

PUBBLICAZIONI 2004

Pubblicazioni su riviste recensite S.C.I.

ISI I.F. 2003

GREZZO	NORM	LAVORI PER EXTENSO
2,993	6	<u>AZZARITI A</u> , <u>XU JM</u> , <u>PORCELLI L</u> , <u>PARADISO A</u> : The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with gefitinib (Iressa™, ZD1839). <i>Biochem Pharmacol</i> 68 (1): 135-44, 2004.
4,733	6	<u>BRANDI M</u> , <u>VICI P</u> , <u>LOPEZ M</u> , <u>VALERIO MR</u> , <u>GIOTTA F</u> , <u>GEBBIA N</u> , <u>SCHITTULLI F</u> , <u>COLUCCI G</u> : Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. <i>Semin Oncol</i> 31 (2 suppl. 5): 13-19, 2004.
3,605	6	<u>BRUNO M</u> , <u>TOMMASI S</u> , <u>STEA B</u> , <u>QUARANTA M</u> , <u>SCHITTULLI F</u> , <u>MASTROPASQUA A</u> , <u>DISTANTE A</u> , <u>DI PAOLA L</u> , <u>PARADISO A</u> : Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a Southern Italian Population. <i>Ann Oncol</i> 15 (suppl. 1): 148-154, 2004.
3,605	6	<u>CIPOLLINI G</u> , <u>TOMMASI S</u> , <u>PARADISO A</u> , <u>ARETINI P</u> , <u>BONATTI F</u> , <u>BRUNETTI I</u> , <u>BRUNO M</u> , <u>LOMBARDI G</u> , <u>SCHITTULLI F</u> , <u>SENSI E</u> , <u>TANCREDI M</u> , <u>BEVILACQUA G</u> , <u>CALIGO MA</u> : Genetic alterations in hereditary breast cancer. <i>Ann Oncol</i> 15 (suppl. 1): 17-113, 2004.
3,894	6	<u>COMELLA P</u> , <u>FRASCI G</u> , <u>CARNICELLI P</u> , <u>MASSIDDA B</u> , <u>BUZZI F</u> , <u>FILIPPELLI G</u> , <u>MAIORINO L</u> , <u>GUIDA M</u> , <u>PANZA N</u> , <u>MANCARELLA S</u> , <u>CIOFFI R</u> : Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. <i>Br J Cancer</i> 91 (3): 489-97, 2004.
3,324	6	<u>DAIDONE MG</u> , <u>PARADISO A</u> , <u>GION M</u> , <u>HARBECK N</u> , <u>SWEEP F</u> , <u>SCHMITT M</u> : Biomolecular features of clinical relevance in breast cancer. <i>Eur J Nucl Med Mol Imaging</i> 31 (suppl. 1): S3-S14, 2004.
10,864	8	<u>DE PLACIDO S</u> , <u>SCAMBIA G</u> , <u>DI VAGNO G</u> , <u>NAGLIERI E</u> , <u>LOMBARDI AV</u> , <u>BIAMONTE R</u> , <u>MARINACCIO M</u> , <u>CARTENI G</u> , <u>MANZIONE L</u> , <u>FEBBRARO A</u> , <u>DE MATTEIS A</u> , <u>GASPARINI G</u> , <u>VALERIO MR</u> , <u>DANESE S</u> , <u>PERRONE F</u> , <u>LAURIA R</u> , <u>DE LAURENTIIS M</u> , <u>GREGGI S</u> , <u>GALLO C</u> , <u>PIGNATA S</u> : Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: multicenter Italian in trials in ovarian cancer (MITO-1) randomized study. <i>J Clin Oncol</i> 22 (13): 2635-42, 2004.
1,088	2	<u>GADALETA C</u> , <u>CATINO A</u> , <u>RANIERI G</u> , <u>ARMENISE F</u> , <u>COLUCCI G</u> , <u>LORUSSO V</u> , <u>CRAMAROSSA A</u> , <u>FIORENTINI G</u> , <u>MATTIOLI V</u> : Radiofrequency thermal ablation of 69 lung neoplasms. <i>J Chemother</i> 16 (suppl. 5): 86-89, 2004.
1,088	2	<u>GADALETA C</u> , <u>COVIELLO M</u> , <u>CATINO A</u> , <u>VENNERI MT</u> , <u>STEA B</u> , <u>QUARANTA M</u> , <u>MATTIOLI V</u> , <u>RANIERI G</u> : Serum vascular endothelial growth factor concentrations in hepatocellular cancer patients undergoing percutaneously radiofrequency thermal ablation. <i>J Chemother</i> 16 (suppl. 5): 7-10, 2004.
2,474	6	<u>GADALETA C</u> , <u>MATTIOLI V</u> , <u>COLUCCI G</u> , <u>CRAMAROSSA A</u> , <u>LORUSSO V</u> , <u>CANNIELLO E</u> , <u>TIMURIAN A</u> , <u>RANIERI G</u> , <u>FIORENTINI G</u> , <u>DE LENA M</u> , <u>CATINO A</u> : Radiofrequency ablation of 40 lung neoplasms: preliminary results. <i>Am J Roentgen</i> 183 (2): 361-68, 2004.
3,894	6	<u>GIANNELLI G</u> , <u>AZZARITI A</u> , <u>FRANSVEA E</u> , <u>PORCELLI L</u> , <u>ANTONACI S</u> , <u>PARADISO A</u> : Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. <i>Br J Cancer</i> 91 (11): 1964-69, 2004.
4,375	6	<u>GIANNELLI G</u> , <u>ERRIQUEZ R</u> , <u>FRANSVEA E</u> , <u>DANIELE A</u> , <u>TREROTOLI P</u> , <u>SCHITTULLI F</u> , <u>GRANO M</u> , <u>QUARANTA M</u> , <u>ANTONACI S</u> : Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. <i>Int J Cancer</i> 109 (5): 782-85, 2004.
1,092	2	ITALIAN NETWORK FOR QUALITY ASSURANCE OF TUMOR BIOMARKERS (INQAT) GROUP (<u>PARADISO A</u>): Interobserver reproducibility of immunohistochemical HER-2/neu evaluation in human breast cancer: the real-world experience. <i>Int J Biol Markers</i> 19 (2): 147-54, 2004.
0,348	1	<u>LORUSSO V</u> , <u>SILVESTRIS N</u> , <u>SPADA M</u> , <u>RANIERI G</u> : Obiettivi della seconda linea di chemioterapia nelle pazienti affette da carcinoma mammario metastatico. <i>Tumori</i> 90 (suppl. 5): S71-75, 2004.
0,348	1	<u>MAIELLO E</u> : Gastric cancer in young age. <i>I Supplimenti di Tumori</i> 3 (3): S153-55, 2004.
1,092	2	<u>MARUBINI E</u> , <u>VERDERIO P</u> , <u>CASINI RAGGI C</u> , <u>PAZZAGLI M</u> , <u>ORLANDO C</u> : Italian Network for Quality Assessment of Tumor Biomarkers; Italian Society of Clinical Chemistry and Clinical Molecular Biology (<u>PARADISO A</u>): Statistical diagnostics emerging from external quality control of real-time PCR. <i>Int J Biol Markers</i> 19 (2): 141-46, 2004.
2,964	4	<u>MORABITO A</u> , <u>GATTUSO D</u> , <u>STANI SC</u> , <u>FANELLI M</u> , <u>FERRAU F</u> , <u>DE SIO L</u> , <u>CASTELLANA MA</u> , <u>LORUSSO V</u> , <u>PRIOLO D</u> , <u>VITALE S</u> , <u>SARMIENTO R</u> , <u>LO VULLO S</u> , <u>MARIANI L</u> , <u>GASPARINI G</u> : Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. <i>Breast Cancer Res Treat</i> 86 (3): 249-58, 2004.
1,150	2	<u>PAPARELLA D</u> , <u>GALEONE A</u> , <u>VENNERI MT</u> , <u>COVIELLO M</u> , <u>VISICCHIO G</u> , <u>CAPPABIANCA G</u> , <u>MASELLI G</u> , <u>MARRAUDINO N</u> , <u>QUARANTA M</u> , <u>DE LUCA TUPPUTI SCHINOSA L</u> : Blood damage related to cardiopulmonary bypass: in vivo and in vitro comparison of two different centrifugal pumps. <i>ASAIO J</i> 50 (5): 473-78, 2004.
0,348	1	<u>PARADISO A</u> , <u>BRUNO M</u> , <u>CICORIA O</u> , <u>DIGENNARO M</u> , <u>LONGO S</u> , <u>RINALDI M</u> , <u>SCHITTULLI F</u> : Analysis of the reasons for accepting or declining participation in genetic research for breast cancer: a hospital-based population study. <i>Tumori</i> 90 (4): 435-36, 2004.
2,932	4	<u>PARADISO A</u> , <u>CARDONE RA</u> , <u>BELLIZZI A</u> , <u>BAGORDA A</u> , <u>GUERRA L</u> , <u>CASAVOLA V</u> , <u>RESHKIN SJ</u> : The Na ⁺ -H ⁺ exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells. <i>Breast Cancer Res</i> 6 (6): R616-28, 2004.
3,605	6	<u>PARADISO A</u> , <u>MUGGIA F</u> : Familial breast cancer screening: ethical and social implications. <i>Ann Oncol</i> 15 (Suppl. 1): 15-16,

		2004.
2,536	4	<u>PARADISO A, RANIERI G, STEA B, ZITO A, ZEHBE I, TOMMASINO M, GRAMMATICA L, DE LENA M</u> : Altered p16INK4a and Fhit expression in carcinogenesis and progression of human oral cancer. <i>Int J Oncol</i> 24 (2): 249-55, 2004.
4,375	6	<u>PARADISO A, XU JM, MANGIA A, CHIRIATTI A, SIMONE G, ZITO A, MONTEMURRO S, GIULIANI F, MAIELLO E, COLUCCI G</u> : Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. <i>Int J Cancer</i> 111 (2): 252-58, 2004.
6,511	6	<u>PARRELLA P, POETA ML, GALLO AP, PRENCIPE M, SCINTU M, APICELLA A, ROSSIELLO R, LIGUORO G, SERIPA D, GRAVINA C, RABITTI C, RINALDI M, NICOL T, TOMMASI S, PARADISO A, SCHITTULLI F, ALTOMARE V, FAZIO VM</u> : Non-random distribution of aberrant promoter methylation of cancer related genes in sporadic breast cancer. <i>Clin Cancer Res</i> 10 (16): 5349-54, 2004.
3,605	6	<u>PERRONE F, MARANGOLO M, DI COSTANZO F, COLUCCI G, REPETTO L, MERLANO M, DE PLACIDO S, TORRI V, COMELLA G, LABIANCA R, PARISI V, GALLO C</u> : Insurance for independent cancer trials. <i>Ann Oncol</i> 15 (11): 1722-3, 2004.
1,092	2	<u>QUARANTA M, COVIELLO M, DANIELE A, ABBATE I, DURRANT LG, PARADISO A, SCHITTULLI F</u> : MUC3 and MCA serum levels and steroid receptor content in breast cancer. <i>Int J Biol Markers</i> 19 (2): 109-14, 2004.
1,256	1	<u>RANIERI G, COVIELLO M, CHIRIATTI A, STEA B, MONTEMURRO S, QUARANTA M, DITTADI R, PARADISO A</u> : Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls. <i>Oncol Rep</i> 11 (2): 435-39, 2004.
1,256	1	<u>RANIERI G, COVIELLO M, PATRUNO R, VALERIO P, MARTINO D, MILELLA P, CATALANO V, SCOTTO F, DE CEGLIE A, QUARANTA M, RIBATTI D, PELLECCCHIA A</u> : Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients. <i>Oncol Rep</i> 12 (4): 817-20, 2004.
2,853	6	<u>RHODES A, BORTHWICK D, SYKES R, AL-SAM S, PARADISO A</u> : The use of cell line standards to reduce HER2/neu assay variation in multiple European Cancer Centers and the potential of automated image analysis to provide for more accurate cut-points for predicting clinical response to trastuzumab. <i>Am J Clin Pathol</i> 122 (1): 51-60, 2004.
2,190	6	<u>RIDOLFI R, ROMANINI A, CHIARION SILENI V, MICHIARA M, GUIDA M, BIASCO G, POLETTI P, AMADUCCI L, LEONI M, RAVAIOLI A</u> on behalf of the Italian Melanoma Intergroup: Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. <i>Melanoma Res</i> 14 (4): 295-99, 2004.
2,536	4	<u>SILVESTRI N, D'APRILE M, ANDREOLA G, LOCOPO N, MARINI L, CRUCITTA E, DE LENA M, LORUSSO V</u> : Rationale for the use of gemcitabine in breast cancer (Review). <i>Int J Oncol</i> 24 (2): 389-98, 2004.
2,614	4	<u>TOMMASI S, FEDELE V, LACALAMITA R, CRAPOLICCHIO A, PERLINO E, BELLIZZI A, PARADISO A</u> : Molecular and functional characteristics of erbB2 in normal and cancer breast cells. <i>Cancer Lett</i> 209 (2): 215-22, 2004.
3,323	6	<u>VOLPI A, BACCI F, PARADISO A, SARAGONI L, SCARPI E, RICCI M, ALDI M, BIANCHI S, MURETTO P, NUZZO F, SIMONE G, MANGIA A, SCHITTULLI F, AMADORI D</u> : Prognostic relevance of histological grade and its components in node-negative breast cancer patients. <i>Mod Pathol</i> 17 (9): 1038-44, 2004.
3,323	6	<u>ZITO FA, MARZULLO F, D'ERRICO D, SALVATORE C, DIGIROLAMO R, LABRIOLA A, PELLECCCHIA A</u> : Quicktime virtual reality technology in light microscopy to support medical education in pathology. <i>Mod Pathol</i> 17 (6): 728-31, 2004.
3,694	6	<u>XU JM, PARADISO A, MCLEOD HL</u> : Evaluation of epidermal growth factor receptor tyrosine kinase inhibitor combined with chemotherapy: need for a more rational design. <i>Eur J Cancer</i> 40 (12): 1807-9, 2004.
100,98	153	TOTALE

Pubblicazioni su riviste non recensite S.C.I.

0,1	<u>DE LENA M</u> : Il cancro questo conosciuto. <i>Puglia Salute</i> Anno 1: 15-17, 2004.
0,1	<u>LORUSSO V, COLUCCI G, BALDUCCI L, COVA D</u> : Patologia neoplastica e invecchiamento: rapporto casuale o casuale?. <i>Geriatric Med Intell</i> 13 (1): 1-17, 2004.
0,1	<u>LORUSSO V, SPADA M, GIAMPAGLIA M, COVA D</u> : Diagnosi e trattamento del tumore della mammella nella donna anziana. <i>Geriatric Med Intell</i> 13 (2): 87-98, 2004.
0,1	<u>MATTIOLI V, FIORE T</u> : Anestesia e sedazione al di fuori della sala operatoria: problematiche anestesiologiche in sala endoscopica. <i>Minerva Anestesiol</i> 70 (9 suppl. 1): 212-16, 2004.
0,1	<u>NARDUCCI AV, GRAMMATICA L</u> : La struttura organizzativa e le funzioni della ricerca in un IRCCS. <i>Tuttosanià</i> Anno XIII n. 73: 36-42, 2004.
0,1	<u>NARDUCCI AV, GRAMMATICA L</u> : Il modello organizzativo per la ricerca osservato in un IRCCS. <i>Tuttosanià</i> Anno XIII n. 73: 54-57, 2004.
0,1	<u>RANIERI G, PATRUNO R, FIORE G, SAPONARO G, PARADISO A, GRAMMATICA L</u> : Thymidine phosphorylase over-expression in oral squamous carcinoma tissue as a potential target of capecitabine. <i>Letters Drug Des & Discovery</i> 1: 45-49, 2004.
0,1	<u>RESTA F, TRIGGIANI V, SABBA C, LICCHELLI B, GHIYASALDIN S, LISO A, SCHITTULLI F, QUARANTA M, PARADISO A, TAFARO E, GUASTAMACCHIA E</u> : The impact of body mass index and type 2 diabetes on breast cancer: current therapeutic measures of prevention. <i>Curr Drug Targets Immune Endocr Metabol Disord</i> 4 (4): 327-33, 2004.
0,1	<u>SCHITTULLI F</u> : Con una diagnosi precoce ed una tecnica chirurgica innovativa si guarisce dal cancro al seno almeno nell'85% dei casi. <i>Puglia Salute</i> Anno 1: 10-11, 2004.
0,9	TOTALE

Libri e capitoli di libri

PARADISO A, CHIRIATTI A: Aspetti genetici e molecolari nella diagnosi e prognosi dei linfomi. In: Libri dell'Istituto Oncologico di Bari. Edizione Artigiangrafica2000 Altamura (BA), pp. 11-36, 2004.

PARADISO A: Biologia e prognosi. In: Neoplasie della mammella: terapia adiuvante. Oncoform Centro Scientifico Editore pp. 8-15, 2004.

D'AMICO C, SCHITTULLI F: Il nuovo TNM dell'American Joint Committee on Cancer Staging System: applicazione ed implicazioni cliniche. In Atti VI Congresso Nazionale di Oncologia Medica. Bologna 21-24 settembre 2004, volume educativo, pp. 3-4.

MATTIOLI V, ALOÈ F, MONTANARO R, BRUNO F: Il dolore neoplastico nel paziente anziano. In: Neoplasie dell'anziano, vol. 2 pp. 179-89, Grafica Ragusa 2004.

Comunicazioni a congressi nazionali ed esteri

AGNELLI G, VERSO M, BERTOGLIO S, AGENO W, BAZZAN M, PARISE P, SALVAGNI S, NAGLIERI E, SANTORO A, LAZZARO A: A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter. *Proceedings ASCO 23*: 730 (abs 8021), 2004.

AMADORI D, SERRA P, TISON C, CASADEI GIUNCHI D, RAVAIOLI A, SISMONDI P, TIENGI A, SCHITTULLI F, PARADISO A, DE LENA M, NANNI O: IBIS 03: adjuvant treatment of biologically aggressive breast cancer (N-, N+1-3): controlled clinical study. *Ann Oncol 15* (suppl. 2): ii25-26 (A74), 2004.

AZZARITI A, XU JM, PORCELLI L, PARADISO A: The enhanced antitumor activity of 7-ethyl-10-hydroxy-camptothecin (SN38) or oxaliplatin in combination with gefitinib ('Iressa', ZD1839) is schedule dependent. *Tumori. I Supplementi di 3* (1): 115 (abs O168), 2004.

BALLATORI E, RUGGERI B, ROILA F, LABIANCA R, COLUCCI G, DI COSTANZO F, PALAZZO S, CASCINU S, SOMBRERO A, PATOIA L: Adjuvant therapies in Italian patients with colorectal cancer. *Ann Oncol 15* (suppl. 2): ii58 (E1), 2004.

BARULLI MR, LORUSSO V, STANGALINO C, MARIANI L, CARACENI A, LEPORE V, PATARNELLO E, GALLUS G, DE LENA M: Cognitive impairment in breast cancer patients submitted to adjuvant chemotherapy. *Ann Oncol 15* (suppl. 2): ii15-16 (A30), 2004.

BRANDI M, D'AMICO C, LONGO S, NOLASCO A, CATALDI A, PETRONI S, SCHITTULLI F: Efficacy and influence of neoadjuvant epirubicin/navelbine chemotherapy (EN) on molecular markers in inflammatory breast cancer (IBC) and preliminary results of a randomized study testing as adjuvant chemotherapy the same en-combination versus docetaxel (TXT). *Atti 6th Milan Breast Cancer Conference. Milano, 16-18 giugno 2004*, pag. 117 (abs H7).

CASAMASSIMA A, PICCIARIELLO M, BERARDINO R, GIAMPAGLIA M, SPADA M, QUARANTA M, LORUSSO V, GUIDA M: Basal levels of bio-humoral markers in metastatic renal cell carcinoma. *J Immunother 27* (6): S13, 2004.

CASAMASSIMA A, PICCIARIELLO M, BERARDINO R, QUARANTA M, LORUSSO V, GUIDA M: c-creative protein: a biomarker of survival in metastatic renal cell carcinoma treated with subcutaneous interleukin-2-based immunotherapy. *Arch Ital Urol Androl 76* (suppl. 1): pag. 23 (abs 60), 2004.

CASAMASSIMA A, RANIERI E, RICCOBON A, BATTAGLIA M, GESUALDO L, NATALI PG, RIDOLFI R, GUIDA M: Vaccination with autologous dendritic cells (DC) pulsed with allogenic highly immunogenic renal carcinoma cell line lysate (RCCLL) or autologous tumour protein lysate in patients with metastatic renal cell carcinoma (MRCC). *International Workshop Cancer Vaccines. Siena 13-15 June 2004*, (comunicazione orale 1/120).

CURTI M, LAZZARI L, MOTTA S, QUERINI R, SIMONE D, ACETI A, TONI F, PICCININ R: BIBLIOSAN: a project to set up a network of the libraries in the Italian Biomedical Research Centres. In: 9. European conference of medical and health libraries (EAHIL). *From Altamira until now: information transference ways. September 20-25, 2004 Santander (Spagna)* p. 70.

DE LENA M, RAMLAU R, HANSEN O, WAGNER L, BARNI S, ALBEROLA V, HUBER R, MITROVIC M, GASMI J, POUGET J-C: Phase II of oral vinorelbine (NVB oral) in combination with cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non small-cell lung cancer (NSCLC): a patient's benefit analysis. *Proceedings ASCO 23*: 697 (abs 7338), 2004.

FABI A, PAPALDO P, CICCARESE M, SALESI N, LORUSSO V, FERRETTI G, CARLINI P, SACCHI I, CECERE F, COGNETTI F: Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: a phase II study. *Proceedings ASCO 23*: 79 (abs 813), 2004.

FABI A, PAPALDO P, CICCARESE M, SALESI N, LORUSSO V, FERRETTI G, DI COCCO B, CARLINI P, CECERE F, PELLICCIOTTA M, MORACE

N, COGNETTI F: Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) combination in metastatic breast cancer (MBC) patients: activity and toxicity. *Ann Oncol 15* (suppl. 2): ii24 (A66), 2004.

FANIZZA G, FALCO G, LABRIOLA A, PATRUNO R, ZITO A, VALERIO P, MARTINO D, RUGGERI E, MONTEMURRO S, RANIERI G: Angiogenetic characterization in primitive abdominal mesotheliomas: possible biological and clinical significance. *Ann Oncol 15* (suppl. 2): ii71 (F15), 2004.

GADALETA C, CATINO A, RANIERI G, ARMENISE F, CONSOLE G, MATTIOLI V: Hypoxic stop-flow perfusion with mytomyacin c as treatment of multifocal liver metastases. *Proceeding Book Fifteenth International Congress on Anti-Cancer Treatment. Paris (FR) 9th -12th february 2004*; pag. 293.

GADALETA C, COVIELLO M, CATINO A, MATTIOLI V, VENNERI AM, STEA B, LARICCHIA G, CILIFRESE V, QUARANTA M, RANIERI G: Serum vascular endothelial growth factor assessment in hepatocellular cancer patients underwent to locally interventional radiology treatments. *Proceeding Book Fifteenth International Congress on Anti-Cancer Treatment. Paris (FR) 9th - 12th february 2004*; pag. 270.

GADALETA G, COVIELLO M, CATINO A, GUGLIOTTA D, VENNERI MT, CILIFRESE V, LARICCHIA G, QUARANTA M, MATTIOLI V, RANIERI G: Serum VEGF concentrations in hepatocellular cancer patients treated with percutaneous radiofrequency thermal ablation. *Ann Oncol 15* (suppl. 2): ii46 (C41), 2004.

GALETTA D, GIOTTA F, RINALDI A, ROMITO S, BRUNETTI C, LORUSSO V, COLUCCI G: Efficacy and tolerability of topotecan in patients with brain metastases from solid tumors. A phase II study of the GOIM (Gruppo Oncologico Italia Meridionale). *Ann Oncol 15* (suppl. 2): ii87 (H20), 2004.

GALETTA D, GIOTTA F, ROSATI G, GEBBIA V, GERMANO D, DI BISCEGLIE M, MANZIONE L, LOGROSCINO F, BORSELLINO N, COLUCCI G: Carboplatino (CB) e raltitrexed ® nel carcinoma squamoso recidivante o metastatico del distretto testa-collo: studio multicentrico del GOIM (Gruppo Oncologico dell'Italia Meridionale). *Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004*; pag. 149.

GEBBIA V, SPADA M, CASSANO G, BRUNETTI C, GERMANO D, NETTIS G, MISINO A, SAMBIASI D, GALETTA D, LORUSSO V: A phase II trial of topotecan and ifosfamide in patients with previously treated, advanced non small cell lung carcinoma (NSCLC). *Proceedings ASCO 23*: 691 (abs 7314), 2004.

GERMANO D, BILANCIA D, DI NOTA A, DELLO RUSSO AM, ROMANO R, ROSATI G, GIOTTA F, MANZIONE L: Bi-weekly oxaliplatin (oxa) and gemcitabine in cisplatin pretreated patients with relapsed ovarian cancer (roc): preliminary data of a phase II trial. *Proceedings ASCO 23*: 473 (abs 5104), 2004.

GIAMPAGLIA M, SPADA M, LATORRE A, CALABRESE R, SAMBIASI D, MISINO A, RINALDI A, MANCARELLA S, VITALE S, LORUSSO V: Capecitabine plus vinorelbine combination in patients with advanced breast cancer. *Ann Oncol 15* (suppl. 2): ii21 (A53), 2004.

GIOTTA F, MANZIONE L, LORUSSO V, CARUSO M, FORTUNATO S, ROMANO RA, ROMITO S, GEBBIA V, VALERIO MR, DURINI E, BRUNETTI C, COLUCCI G: Mitoxantrone + prednisone versus taxotere + prednisone nel trattamento del carcinoma prostatico ormonorefrattario (cpor). *Studio rdomizzato di fase II del Gruppo Oncologico dell'Italia Meridionale (GOIM). Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004*; pag. 151.

GIULIANI F, BORSELLINO N, MAIELLO E, SIMONE B, GEBBIA V, LOPEZ M, MANZIONE L, MOLICA S, COLUCCI G: Studio clinico di fase II con la associazione UFT + irinotecan nel trattamento del carcinoma coloretale in fase avanzata del Gruppo Oncologico dell'Italia Meridionale (prof. GOIM 2302). *Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004*; pag. 134-35.

- GIULIANI F, DI BISCEGLIE M, VINCIARELLI G, MAIELLO E, GALETTA D, NAGLIERI E, GIOTTA F, SIMONE B, MALLAMACI R, COLUCCI G: Cisplatino (Cddp) + gemcitabina (Gem) nel trattamento del carcinoma del fegato, colecisti e vie biliari. Studio di fase II. Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004; pag. 137.
- GIULIANI F, MAIELLO E, MOLICA S, BATTAGLIA C, GEBBIA N, DI BISCEGLIE M, VINCIARELLI G, COLUCCI G: Irinotecan (CPT-11) and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Proceedings ASCO 23: 371 (abs 4235), 2004.
- GIULIANI F, MAIELLO E, MOLICA S, GEBBIA N, DI BISCEGLIE M, BATTAGLIA C, VINCIARELLI G, COLUCCI G: Irinotecan (CPT-11) and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer (AGC) patients. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol 15 (suppl. 2): ii76 (F38), 2004.
- GIULIANI F, MANZIONE L, DI BISCEGLIE M, MAIELLO E, ROMITO S, ROMANO R, COLUCCI G: Irinotecan (Cpt-11) + mitomicina (MMC) + capecitabina (Cap) nel trattamento del carcinoma gastrico avanzato. Studio di fase I del Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2401). Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004; pag. 154.
- GIULIANI F, MOLICA S, MAIELLO E, BATTAGLIA C, DI BISCEGLIE M, GEBBIA N, VALERIO MR, VINCIARELLI G, COLUCCI G: Terapia di seconda linea del carcinoma gastrico avanzato con la combinazione irinotecan (Cpt-11) + mitomicina (MMC). Studio di fase II del Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2106). Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004; pag. 132.
- GUIDA M, BARULLI MR, STANGALINO C, MARIANI L, CARACENI A, LEPORE V, LIVREA P, DE CARO MF, GALLUS G, LORUSSO V: Impairment of cognitive function in patients submitted to adjuvant chemotherapy for early breast cancer: a follow up study. Proceedings ASCO 23: 732 (abs 8027), 2004.
- GUIDA M, CASAMASSIMA A, PICCIARIELLO M, BERARDINO R, RANIERI C, MONTENEGRO E, QUARANTA M, LORUSSO V: CRP: a biomarker of survival in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based immunotherapy. Ann Oncol 15 (suppl. 2): ii40 (C14), 2004.
- IAFFAIOLI RV, FORMATO R, TORTORIELLO A, PISANO A, DEL PRETE S, CIGOLARI S, PISCONTI V, MANZIONE L, GIOTTA F and other GOIM authors: Preliminary data of GOIM 2107 study: multicenter phase II study of sequential hormone therapy with anastrozole/exemestane in metastatic breast disease. Proceedings ASCO 23: 81 (abs 820), 2004.
- IONTA MT, SCANU A, ATZORI F, VACCA D, CONTU A, FARRIS A, LORUSSO V, PALMERI S, MINERBA L, MASSIDDA B: Unexpectedly high survival rate in very poor prognosis stage III B breast cancer patients receiving cisplatin-based primary chemotherapy. A multicenter Italian study. Proceedings ASCO 23: 28 (abs 605), 2004.
- IONTA MT, SCANU A, CARTA AM, PUSCEDDU V, FARRIS A, CONTU A, LORUSSO V, PALMERI S, MINERBA L, MASSIDDA B: Feasibility and safety of breast conservation surgery after tumor downstaging by primary chemotherapy in locally advanced stage III B breast cancer (LABC) patients. Ann Oncol 15 (suppl. 2): ii15 (A26), 2004.
- LAGATTOLLA F, FALLACARA A, GIULIANI F, COLUCCI G: La uscoterapica nella relazione con il paziente oncologico. Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004; pag. 150.
- LATORRE A, DECIO R, CALABRESE R, GIAMPAGLIA M, SPADA M, LORUSSO V: Phase II trial with topotecan and ifosfamide combination in the treatment of recurrent ovarian cancer. Ann Oncol 15 (suppl. 2): ii93 (L10), 2004.
- LORUSSO V, CALABRESE R, LATORRE A, GUIDA M, MISINO A, SPADA M, PARADISO A, DE LENA M: A phase II randomized trial of cisplatin/paclitaxel plus lisdamine versus cisplatin/ifosfamide plus lisdamine in the treatment of ovarian cancer. Proceedings ASCO 23: 875 (abs 9678), 2004.
- MAIELLO E, GIULIANI F, ROMITO S, PEZZELLA G, MALLAMACI R, DI RENZO G, DI BISCEGLIE M, COLUCCI G: Folfiri vs folfiri + celecoxib nel trattamento del carcinoma del colon-retto avanzato. Studio randomizzato di fase II del Gruppo Oncologico dell'Italia Meridionale (GOIM). Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004; pag. 157.
- MAIELLO E, LOPEZ M, IAFFAIOLI RV, TAMBARO R, PAOLETTI G, GIULIANI F, COLUCCI G: A dose finding followed by a phase II study of oral UFT (uracil/tegafur) and Iv (leucovorin) plus i.v. mitomycin (MMC) in patients (pts) with metastatic colorectal cancer (MCRC): phase I results. Proceedings ASCO 23: 297 (abs 3709), 2004.
- MAIER S, NIMMIRICH I, MARX A, EPPENBERGER-CASTORI S, JAENICKE F, PARADISO A, SPYRATOS F, FOEKENS J, SCHMITT M, HARBECK N: DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients. Proceedings ASCO 23: 8 (abs 525), 2004.
- MANGIA A, CHIRIATTI A, RANIERI G, SALVATORE C, ABBATE I, MONTEMURRO S, DI LEO A, BERLOCO P, PARADISO A: Helicobacter pylori infection and angiogenesis factors in gastric cancer carcinoma. Proceedings AACR 45: 831 (abs 3605), 2004.
- MATTIOLI V, FIORE T, ARMENISE F, CANNIELLO E, D'ALUISIO L, DIELE K, GADALETA C: Total intravenous anesthesia (TIVA) and differential ventilation cmv/cpap in radiofrequency ablation (RFA) of lung tumors under ct guidance. Minerva Anestesiol 70 (9 suppl. 2): 295, 2004.
- MATTIOLI V, MONTANARO R, CHIUMARULO F, ALOÈ F: Valutazione della sindrome del burnout nel quartiere operatorio di un istituto oncologico. Minerva Anestesiol 70 (9 suppl. 2): 485-86, 2004.
- PARADISO A, AZZARITI A, PORCELLI L, SIMONE GM, FRANSVEA E, ANTONACI S, GIANNELLI G: Gefitinib in liver cancer: could laminin-5 expression be a good. EJC Suppl 2 (8): 120 (poster 400), 2004.
- PARADISO A, CHIRIATTI A, TOMMASI S, LACALAMITA R, SALVATORE C, LATORRE A, LORUSSO V, MANGIA A: Prediction of paclitaxel clinical response in advanced breast cancer patients: any role for B-tubulin alterations. Int J Biol Markers 19 (suppl. 3): S40, 2004.
- PARADISO A, TOMMASI S, FEDELE V, LACALAMITA R, BRUNO M, MOORE D, CRAPOLICCHIO A, SCHITTULLI F, GINZINGER D, SCOTT G, EPPENBERGER-CASTORI S, EPPENBERGER U BENZ CC: ErbB2 SNPs in Caucasian women with familial breast cancer. Breast Cancer Res Treat 88 (suppl. 1): S163 (abs 4043), 2004.
- PARADISO A, XU JM, AZZARITI A: Sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatin: persistence of apoptosis and inhibition of platinum-DNA adduct removal by ZD1839. Tumori. I Supplementi di 3 (1): 133 (abs P205), 2004.
- PARRELLA P, POETA ML, GALLO AP, MARIA P, SCINTU M, SERIPA D, GRAVINA C, RABITTI C, RINALDI M, TOMMASI S, PARADISO A, APICELLA A, ROSSIELLO R, FAZIO VM: Promoter hypermethylation profiles of sporadic primary breast cancer and benign breast lesions. Proceedings AACR 45: 1149 (abs 4975), 2004.
- PATARNELLO E, BARULLI MR, SPADA M, GIAMPAGLIA M, LORUSSO V: Quality of life assessment in cancer patients. Ann Oncol 15 (suppl. 2): ii106 (N19), 2004.
- PATRUNO R, COVIELLO M, QUARANTA M, VALERIO P, MARTINO D, CATALANO V, SCOTTO F, DE CEGLIE A, RANIERI G, PELLECCCHIA A: Vascular endothelial growth factor concentrations in plasma-activated platelets-rich blood compartments from healthy controls and colorectal cancer patients. Ann Oncol 15 (suppl. 2): ii43-44 (C31), 2004.
- PELLECCCHIA A, LABRIOLA A, PATRUNO R, DAPRILE R, SCOTTO F, DE CEGLIE A, MARTINO D, VALERIO P, ZITO AF, RANIERI G: Thymidine phosphorylase characterization in healthy and cancerous pancreatic tissue: an emerging target for capecitabine. Ann Oncol 15 (suppl. 2): ii73 (F25), 2004.

PELLECCHIA A, COVIELLO M, PATRUNO R, VALERIO P, MARTINO D, CATALANO V, SCOTTO F, DE CEGLIE A, QUARANTA M, RANIERI G: Vascular endothelial growth factor concentrations in plasma-activated platelets rich of healthy controls and colorectal cancer patients. Atti VI Congresso Nazionale di Oncologia Medica Bologna 21-22 settembre 2004; poster C 031.

PELLECCHIA A, LABRIOLA A, PATRUNO R, DAPRILE R, SCOTTO F, DE CEGLIE A, MARTINO D, VALERIO P, ZITO AF, RANIERI G: Thymidine phosphorylase Characterization in healthy and cancerous pancreatic tissue: an emerging target for capecitabine. Atti VI Congresso Nazionale di Oncologia Medica. Bologna 21-22 settembre 2004; poster F 025.

PINTO C, MARINO A, DE PANGHER MANZINI V, BENEDETTI G, GALETTA D, PANETTA A, MAZZANTI P, DEL CONTE G, PIANA E, LOPEZ M, MARTONI A: Multicentric Italian phase II study (SITMP1) of sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in 54 untreated malignant pleural mesotheliomas (MPM). Ann Oncol 15 (suppl. 2): ii35 (B32), 2004.

PORCELLI L, AZZARITI A, XU JM, SIMONE MG, PARADISO A: Exposure of HT-29 and LoVo cells to the EGFR tyrosine kinase inhibitor gefitinib (Iressa™, ZD1839) and the antiangiogenic agent ZD6474: Modulation of tyrosine kinase receptors and their signal transduction pathway. Proceedings AACR 45: 1075 (abs 4655), 2004.

PORCELLI L, AZZARITI A, PARADISO A: Combination of ZD6474 and 7-ethyl-10-hydroxy-camptothecin (SN-38) or oxaliplatin: in vitro study. Tumori. I Supplementi di 3 (1): 134 (abs P208), 2004.

RANIERI G, PATRUNO R, SAPONARO G, CONSOLE G, PARADISO A, GRAMMATICA L: Thymidine phosphorylase overexpression in oral cancer tissue as a target of capecitabine: the preclinical rationale. Ann Oncol 15 (suppl. 2): ii47 (C47), 2004.

ROILA F, RUGGERI B, BALLATORI E, LABIANCA R, PATOIA L, COLUCCI G, DI COSTANZO F, PALAZZO S, CASCINU S, SOBRERO A: Adjuvant therapies in patients with colorectal cancer: an audit on clinical practice in Italy. Proceedings ASCO 23: 282 (abs 3648), 2004.

SCAGLIOTTI G, ROSSI A, NOVELLO S, DE MARINIS F, DOGLIOTTI L, CRINÒ L, LORUSSO V, MARTONI A, PACCAGNELLA A, GRIDELLI C: Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). Proceedings ASCO 23: 633 (abs 7081), 2004.

SERRONE L, FRESCHI A, CHIARION-SILENI V, RIDOLFI R, TOMA S, GUIDA M, COGNETTI F: Radiotherapy followed by temozolomide in the treatment of patients with melanoma metastatic to the brain: an Italian multicenter study. Proceedings ASCO 23: 721 (abs 7558), 2004.

SIMONE G, MANGIA A, CRISTIANI S, STEA B, SICILIANO M, WIESEL S, PARADISO A: Features of cytological grade and prognosis in breast cancer. Cytopathology 15 (suppl. 2): 11-12 (abs 35), 2004.

SPADA M, GIAMPAGLIA M, MILANDRI C, AMADORI D, ZOLI W, LORUSSO V, DE LENA M: Taxol plus lonidamine combination in unresectable hepatocarcinoma. A phase I study. Ann Oncol 15 (suppl. 2): ii75 (F33), 2004.

TOMMASI S, FEDELE V, BRUNO M, CRAPOLICCHIO A, SCHITTULLI F, GINZINGER D, SCOTT G, EPPENBERGER-CASTORI S, EPPENBERGER U, BENZ CC, PARADISO A: Familial breast cancer risk and ErbB2 single nucleotide polymorphism frequency. Int J Biol Markers 19 (suppl. 3): S49, 2004.

TOMMASI S, MANGIA A, LACALAMITA R, BELLIZZI A, FEDELE V, CHIRIATTI A, LATORRE A, LORUSSO V, PARADISO A: Beta-tubulin: biological and clinical relevance in breast cancer. Tumori. I Supplementi di 3 (1): 138 (abs P216), 2004.

VICI P, FOGGI P, CONTI F, DI LAURO L, AMODIO A, SERGI D, MASI MC, CAUCHI C, GIOTTA F, GEBBIA V, COLUCCI G, LOPEZ M: Docetaxel e vinorelbina nel carcinoma mammario metastatico pretrattato con antracicline – studio multicentrico di fase II (GOIM 2005). Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004; pag. 143.

VICI P, GIOTTA F, GEBBIA V, COLUCCI G, LORUSSO V, DI LULLO L, PAOLETTO G, CONTI F, FOGGI P, MANCARELLA S, LOPEZ M: Gemcitabina e docetaxel nel trattamento di prima linea del carcinoma mammario metastatizzato – studio multicentrico di fase II – GOIM 2105. Atti VII Congresso Nazionale GOIM: L'evoluzione della terapia dei tumori. Roma 23-25 giugno 2004; pag. 158.

ZIZZO N, PATRUNO R, LIONETTI A, LABRIOLA A, MATTIOLI E, DAPRILE R, ZITO AF, BUFO P, RANIERI G: Dog lymphoma as an interspecies spontaneous model of tumour angiogenesis. Ann Oncol 15 (suppl. 2): ii80 (G14), 2004.

Andamento delle pubblicazioni 2000-2004

Anno	Pubblicazioni per eXteNso		Libri e Capitoli di libro	Abstracts	Totale
	Recensite	Non recensite			
2000	17	11	6	63	97
2001	17	23	4	28	74
2002	30	6	2	10	48
2003	26	22	4	41	93
2004	35	7	4	67	113
Totale	125	69	20	209	425

Andamento Impact Factor grezzo e normalizzato 2000 - 2004

